Our mission is to provide the medical community with multi-disciplinary educational tools that address their clinical needs and help in their daily clinical practice.


The introduction of biologic therapies to treat a wide variety of immune-mediated inflammatory diseases (IMIDs), in rheumatology, gastroenterology, dermatology and oncology, among others, had a significant impact on the way these diseases are treated. However, the high cost of biologics and differences in reimbursement systems, big differences in their adoption have been seen across the competent regulatory authorities’ countries. Consequently, many patients eligible, from a clinical perspective, to receive a biologic treatment do not receive the adequate treatment due to cost constraints, which adds to their disease burdens and affects their quality of life.

Biosimilars are approved by competent regulatory authorities based on robust evidence of biosimilarity, and are high quality, affordable alternatives to originator biologics. The potential cost savings from their introduction are believed to help alleviate the ever-increasing pressure on healthcare systems. Patients also benefit as more resources are freed up, allowing more patients eligible for a biologic to be treated in a timely, efficient and sustained manner.

Steering committee


Prof. Hubertus H. Nietsch

Chief of Medicine and Division Head, Martin‑Luther University of Halle-Wittenberg, Halle (Saale), Germany

Prof. Nietsch, MD serves as Chief of Medicine and  Division Head of St. Elisabeth Medical Center, a 650-bed academic teaching hospital of Martin-Luther-University Halle, Germany. He also holds a faculty position at Albany Medical Center, NY, USA. He completed his medical training at Munich University and University College Dublin, Ireland, followed by postgraduate fellowships at the University of Vermont and University of Washington, Seattle. 

His main interests in gastroenterology are the management of patients with complex GI problems, including inflammatory bowel disease and interventional endoscopy. He is a member of DGVS, ASGE and AGA. He serves on the editorial board of national and international GI journals.

Prof. Nietsch has no disclosures to share

Prof. Luis Puig

Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau (HSCSP), Barcelona, Spain

Prof. Luis Puig Sanz is Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau (HSCSP), and Professor of Dermatology at the Universitat Autònoma de Barcelona (UAB) Medical School, both in Barcelona, Spain.

To date, Prof. Puig’s clinical research has focused on psoriasis, atopic dermatitis, urticaria, and hidradenitis suppurativa, and he has participated in over 100 clinical trials and research projects. He is considered to be a key opinion leader in this field, both nationally and internationally, having conducted 600 presentations at national and international conferences, workshops, and seminars. He is co-author of the Dermatology Textbook "Dermatología Clínica", edited by Prof. Carlos Ferrándiz, widely accepted and recommended in many Medical Schools of Spain and Latin America. He is a member of the Editorial Board of many dermatology journals including Dermatology, Actas Dermosifiliográficas, Journal of Psoriasis and Psoriatic Arthritis, Medicina Cutánea Latinoamericana, Piel, Medicina Clínica, and reviewer for Archives of Dermatology, British Journal of Dermatology, Dermatology, Journal of Investigative Dermatology, Acta Dermato-Venereologica, and the Journal of the European Academy of Dermatology, among others.

Prof. Puig Sanz is Co-chair of the Task Force on Psoriasis for the EADV, was a member of the EADV Board of Directors and a member of the EADV Nomination and Elections Committee (2013−19). He is currently Councillor (2012−) and a board member (2018−) of the International Psoriasis Council, and a member of the Skin Inflammation and Psoriasis International Network and the Fondation René Touraine, of which he was President until 2019. He is a member of several other scientific committees including the European Scientific Committee - Dermatology, European Center for Clinical Excellence, and European Dermatology Forum. 


Luis Puig Sanz receives honoraria for speaking and consulting from: AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Fresenius-Kabi, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, UCB.

Prof. Puig Sanz has participated in company-sponsored speaker’s bureaus for: Celgene, Janssen, Lilly, Novartis, Pfizer.

Grants and research support have been received from: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, UCB.

Prof. Hendrik Schulze‑Koops

Head of the Department of Rheumatology, Munich University Hospital, Munich, Germany

Prof. Hendrik Schulze-Koops received his doctorate of medicine from the University of Hamburg, Germany, in 1988 for his work on the arthritogenic factors of Yersinia. He was promoted to Professor of Clinical Immunology at the University of Erlangen-Nuremberg, Germany, in 2006, and since then has held the position of Professor of Internal Medicine and Rheumatology at Munich University Hospital, Germany. With nearly 30 years' experience in the field of clinical immunology, Prof. Schulze-Koops is one of the foremost authorities in rheumatism.

Prof. Schulze-Koops' current research focuses on cellular and molecular pathogenesis of autoimmune diseases, and he is currently leading research into mechanisms of sustained autoimmune T-cell activity in diseases, such as rheumatoid arthritis with the two important aspects of increased activity of inflammatory effector T cells and decreased functionality of regulatory T cells.


The Division of Rheumatology and Clinical Immunology of the University of Munich receives financial support from AbbVie, Amgen, AstraZeneca, Biogen, BMS, Celgene, Celltrion, Fresenius, Gilead, GSK, Hospira, Janssen-Cilag, Lilly, Medac, MSD,  Mundipharma, Mylan, Novartis, Pfizer, Sanofi-Aventis, Hexal Sandoz, Shire Baxalta, Sobi, Roche, UCB

Hendrik Schulze-Koops receives honoraria for lectures and consultations from AbbVie, Amgen, AstraZeneca, Biogen International, BMS, Boehringer Ingelheim, Celgene, Celltrion, Gilead, GSK, Hospira, Janssen-Cilag, Lilly, Medac, MSD, Merck, Mundipharma, Mylan, Novartis, Pfizer, Sanofi-Aventis, Hexal Sandoz, Roche, UCB

Steering Committee members


Prof. Giampiero Girolomoni

University of Verona, Italy

Prof. Miriam Wittmann 

University of Leeds, UK

Prof. Peter Weisenseel

Dermatologikum Hamburg, Germany


Prof. Yoram Bouhnik

Hôpital Beaujon, Paris Diderot University, France 

Prof. Flavio Caprioli

Università degli Studi di Milano, Italy 

Prof. João Gonçalves

University of Lisbon, Portugal

Dr Fraser Cummings

Southampton General Hospital, UK


Prof. Maria Cuadrado

Clínica Universidad de Navarra, Madrid, Spain

Prof. Bruno Fautrel

Université Pierre et Marie Curie, Paris, France

Prof. Tore Kvien

University of Oslo, Norway

Prof. Maurizio Cutolo

University of Genova, Italy

Prof. Carlo Selmi

Rheumatology and Clinical Immunology, Humanitas Research Hospital, Humanitas University Milan, Italy

Dr Raj Sengupta

Royal United Hospitals and University of Bath, UK

Prof. Alla Skapenko

Ludwig-Maximilians-Universität Munich, Germany

Prof. Peter Taylor

University of Oxford, UK